Latest news
New vaccine technology could protect from future viruses and variants
Studies of a ‘future-proof’ vaccine candidate have shown that just one antigen can be modified to provide a broadly protective immune response in animals.
Antiviral drug linked to SARS-CoV-2 mutations
Researchers have uncovered a link between an antiviral drug for COVID-19 infections called molnupiravir and a pattern of mutations in the SARS-CoV-2 virus.
Researchers reveal how microbes return after a wildfire
A study suggests that dispersal - through air or rain, for example - plays a major role in microbial succession after a destructive fire.
TeselaGen Biotechnology renews partnership with Joint BioEnergy Institute
TeselaGen Biotechnology has announced that it is extending its relationship with Joint BioEnergy Institute (JBEI) through 2027 via a new multi-year contract.
Nanoparticles made from plant viruses could be farmers’ new ally
Engineers have developed nanoparticles, fashioned from plant viruses, that can deliver pesticide molecules to soil depths that were previously unreachable.
Climate warming could impact forest resilience by disrupting fungal networks
Researchers find that warming trends will likely result in major disturbances of networks of fungi, potentially harming forest resilience.
Antiviral drug linked to SARS-CoV-2 mutations
Researchers have uncovered a link between an antiviral drug for COVID-19 infections called molnupiravir and a pattern of mutations in the SARS-CoV-2 virus.
Researchers reveal how microbes return after a wildfire
A study suggests that dispersal - through air or rain, for example - plays a major role in microbial succession after a destructive fire.
Climate warming could impact forest resilience by disrupting fungal networks
Researchers find that warming trends will likely result in major disturbances of networks of fungi, potentially harming forest resilience.
MEMCOM AWARDS 2023
The Microbiologist has been shortlisted for the MEMCOM award for Best Magazine Launch or Re-launch. Subscribe now to make sure you don't miss out on the latest news, features, careers and opinion.
Subscribe
TeselaGen Biotechnology renews partnership with Joint BioEnergy Institute
TeselaGen Biotechnology has announced that it is extending its relationship with Joint BioEnergy Institute (JBEI) through 2027 via a new multi-year contract.
NICER than CRISPR: new gene editor reduces unintended mutations
Researchers led by Osaka University develop a new gene modification technique known as NICER that significantly reduces off-target mutations in DNA.
Researchers awarded €1.8 million to commercialise cultivated meat
Three companies have received a total of €1.8 million from EIT Food to develop innovative products to reduce the cost of producing cultivated meat within the next two years.
New vaccine technology could protect from future viruses and variants
Studies of a ‘future-proof’ vaccine candidate have shown that just one antigen can be modified to provide a broadly protective immune response in animals.
Nanoparticles made from plant viruses could be farmers’ new ally
Engineers have developed nanoparticles, fashioned from plant viruses, that can deliver pesticide molecules to soil depths that were previously unreachable.
Scientists develop mRNA vaccine against Lyme disease-causing bacteria
An experimental mRNA vaccine provides protection in preclinical animal models against infection from Borrelia burgdorferi, the bacterium that causes Lyme disease, according to new research.
TeselaGen Biotechnology renews partnership with Joint BioEnergy Institute
TeselaGen Biotechnology has announced that it is extending its relationship with Joint BioEnergy Institute (JBEI) through 2027 via a new multi-year contract.
Lumen Bioscience wins historic $1.5 million Wilkes Center Climate Prize
The Seattle-based biotech company has developed a natural solution to eliminate the microorganisms in the cow gut that produces methane gas, a major cause of global warming.
Clinical trial of HIV vaccine begins in United States and South Africa
A trial of a preventive HIV vaccine candidate has begun enrollment in the United States and South Africa. The Phase 1 trial will evaluate a novel vaccine known as VIR-1388 for its safety and ability to induce an HIV-specific immune response in people.
